GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (BOM:500674) » Definitions » Institutional Ownership

Sanofi India (BOM:500674) Institutional Ownership : 16.63% (As of Jul. 19, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Sanofi India Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sanofi India's institutional ownership is 16.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sanofi India's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sanofi India's Float Percentage Of Total Shares Outstanding is 0.00%.


Sanofi India Institutional Ownership Historical Data

The historical data trend for Sanofi India's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Institutional Ownership Chart

Sanofi India Historical Data

The historical data trend for Sanofi India can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30
Institutional Ownership 17.09 17.06 16.90 16.67 16.49 16.57 16.62 16.55 16.62 16.63

Sanofi India Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sanofi India Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.

Sanofi India Headlines

No Headlines